Yahoo
Toronto - Delayed Quote CAD

Bausch Health Companies Inc. (BHC.TO)

11.47 -0.94 (-7.57%)
At close: October 30 at 4:00:00 PM EDT
Chart Range Bar
Loading chart for BHC.TO
  • Previous Close 12.41
  • Open 12.43
  • Bid 11.47 x --
  • Ask 11.48 x --
  • Day's Range 11.43 - 12.64
  • 52 Week Range 6.10 - 12.65
  • Volume 1,717,681
  • Avg. Volume 675,945
  • Market Cap (intraday) 4.293B
  • Beta (5Y Monthly) 0.37
  • PE Ratio (TTM) --
  • EPS (TTM) -3.14
  • Earnings Date Oct 28, 2026
  • Forward Dividend & Yield -- (0.00%)
  • Ex-Dividend Date Nov 10, 2010
  • 1y Target Est --

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company. It operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The company develops, manufactures, and markets products primarily in the therapeutic areas of gastroenterology, hepatology, neurology and dermatology, generic and branded generic pharmaceuticals, dentistry products, over-the-counter products, aesthetic medical devices, and eye health. The company sells its products in the United States, China, Canada, Poland, Mexico, France, South Korea, Russia, Japan, Germany, the United Kingdom, Spain, Italy, Czech Republic, Slovakia, Ukraine, Bulgaria, and internationally. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

www.bauschhealth.com

20,300

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P/TSX Composite index (^GSPTSE) .

YTD Return

BHC.TO
19.60%
S&P/TSX Composite index (^GSPTSE)
11.78%

1-Year Return

BHC.TO
24.00%
S&P/TSX Composite index (^GSPTSE)
18.03%

3-Year Return

BHC.TO
24.13%
S&P/TSX Composite index (^GSPTSE)
88.90%

5-Year Return

BHC.TO
66.94%
S&P/TSX Composite index (^GSPTSE)
69.32%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q3 FY26
Revenue 2.94B
Earnings 436M
Profit Margin 14.82%

Q4

FY25

Q1

FY26

Q2

FY26

Q3

FY26

-1B
0
1B
2B
-40.0%
-20.0%
0.0%

Analyst Insights

View More

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 10/29/2026
Analyst Jefferies
Rating Action Maintains
Rating Hold
Price Action Raises
Price Target 6.5 -> 8

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -7.57%

  • Return on Assets (ttm)

    7.22%

  • Return on Equity (ttm)

    -11,040.00%

  • Revenue (ttm)

    11.11B

  • Net Income Avi to Common (ttm)

    -841M

  • Diluted EPS (ttm)

    -3.14

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    2.48B

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    1.64B

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: